Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

KOL urges offering Profound’s TULSA-PRO to prostate cancer patients as part of informed consent

Y. Mark Hong, M.D., a key opinion leader (KOL) and world recognized urologist, suggests that if physicians aren’t offering or at least talking to their prostate cancer patients about Profound Medical’s (NASDAQ:PROF;...

April 11, 2023

Developments

Cantor eyes next NASH readout for Hepion’s rencofilstat

Cantor Fitzgerald is eagerly awaiting data from Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2 ALTITUDE-NASH liver function trial with its cyclophilin inhibitor, rencofilstat, guided for the second quarter of 2023. “We...

April 11, 2023

Developments

OpSens completes enrollment in SavvyWire study in Europe

OpSens (TSX:OPS; OTCQX:OPSSF) completed enrollment in the SAFE–TAVI clinical study, which is studying left ventricular rapid pacing using SavvyWire in transcatheter aortic valve implantation (TAVI or TAVR) procedures...

April 11, 2023

Executive Moves

NervGen appoints Michael Kelly as president, CEO

NervGen Pharma (TSXV:NGEN; OTCQX:NGENF) named Michael Kelly to the position of president and CEO, effective April 10, as well as a member of the board. In a statement, Bill Radvak, executive chairman of NervGen, said Mr...

April 10, 2023

Developments

Vistagen receives new European patent for AV-101

The European Patent Office granted Vistagen (NASDAQ:VTGN) a patent for AV-101, its oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist, a potential new oral treatment alternative for multiple CNS...

April 6, 2023

Markets

WB starts CymaBay at OP citing de-risked late-stage asset

William Blair launched coverage of CymaBay Therapeutics (NASDAQ:CBAY) with an “outperform” rating. The stock closed at $8.66 on April 3. CymaBay is advancing seladelpar, a selective peroxisome proliferator-activated...

April 5, 2023

Developments

Miromatrix, CareDx in pact for bioengineered organs in human transplant

Miromatrix Medical (NASDAQ:MIRO) and CareDx (NASDAQ:CDNA) entered an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs. CareDx will develop an...

April 5, 2023

Developments

iBio discovers new panel of CD3 T-cell binding antibodies using AI epitope steering platform

iBio (NYSEA:IBIO) announced the discovery of a panel of CD3 T-cell binding antibodies, representing an important first step for the company into bispecific immuno-oncology therapies. T-cell-redirecting bispecific...

April 5, 2023

Developments

PharmaJet to present immune response DNA vaccine data

Closely-held PharmaJet will present results of a comprehensive review of published scientific literature comparing data associated with various DNA vaccine delivery methods at the World Vaccine Congress 2023 on April 5...

April 4, 2023

Developments

Eckert & Ziegler to supply POINT Biopharma with Actinium-225

A subsidiary of POINT Biopharma Global (NASDAQ:PNT) signed an agreement for the supply of Actinium-225 (non-carrier-added Ac-225) from Eckert & Ziegler Strahlen EUZ (ETR) of Germany for POINT’s pipeline of next...

April 4, 2023

Developments

PharmaJet partner seeks EUA in India for needle-free Omicron booster

PharmaJet partner, Gennova Biopharmaceuticals, filed data for its mRNA-based Omicron specific COVID-19 booster shot for emergency use authorization (EUA) to the office of the Drug Controller General of India. The...

April 3, 2023

Markets

Dawson James ups NRx Pharma PT to $9 from $3

Dawson James Securities raised its price target for NRx Pharmaceuticals (NASDAQ:NRXP) to $9 from $3, saying the company’s NRX-101 drug candidate could change the treatment paradigm for depression, PTSD, and related...

April 3, 2023

General

More